Show simple item record

dc.contributor.authorYanik, Gregory A.
dc.contributor.authorParisi, Marguerite T.
dc.contributor.authorShulkin, Barry L.
dc.contributor.authorNaranjo, Arlene
dc.contributor.authorKreissman, Susan G.
dc.contributor.authorLondon, Wendy B.
dc.contributor.authorVillablanca, Judith G.
dc.contributor.authorMaris, John M.
dc.contributor.authorPark, Julie R.
dc.contributor.authorCohn, Susan L.
dc.contributor.authorMcGrady, Patrick
dc.contributor.authorMatthay, Katherine K.
dc.date2022-08-11T08:10:46.000
dc.date.accessioned2022-08-23T17:18:55Z
dc.date.available2022-08-23T17:18:55Z
dc.date.issued2013-04-01
dc.date.submitted2014-01-25
dc.identifier.citationYanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr;54(4):541-8. doi: 10.2967/jnumed.112.112334. Epub 2013 Feb 25. PubMed PMID: 23440556. <a href="http://dx.doi.org/10.2967/jnumed.112.112334">Link to article on publisher's site</a>
dc.identifier.issn0161-5505 (Linking)
dc.identifier.doi10.2967/jnumed.112.112334
dc.identifier.pmid23440556
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47961
dc.description<p>This study was supported in part by Grant CA-29511 from the National Cancer Institute for the IROC Rhode Island (QARC), a quality assurance vehicle and data management service for diagnostic imaging and radiation oncology for the National Cancer Institute Clinical Trials Program. QARC is a research program within the University of Massachusetts Medical School led by Dr. Thomas (TJ) FitzGerald of the Department of Radiation Oncology.</p>
dc.description.abstractRadiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for a cohort of patients with high-risk metastatic disease. METHODS: mIBG scans from 280 patients with mIBG-avid, stage 4 neuroblastoma enrolled on the Children's Oncology Group (COG) protocol A3973 were evaluated at diagnosis (n = 280), after induction chemotherapy (n = 237), and after an autologous stem cell transplantation (n = 178). Individual mIBG scans were evaluated at 10 different anatomic regions, with the scoring of each site (0-3) based on the extent of disease at that anatomic region. RESULTS: There was no correlation between CS at diagnosis and subsequent treatment outcome. Patients with a CS > 2 after induction therapy had a significantly worse event-free survival (EFS) than those with scores 2 identified a cohort of patients at greater risk for an event, independent of other known neuroblastoma factors, including age, MYCN status, ploidy, mitosis-karyorrhexis index, and histologic grade. For MYCN-amplified tumors, the presence (CS > 0) versus absence (CS = 0) of residual mIBG avidity after induction was associated with a significantly worse outcome (3-y EFS: 11.8% +/- 7.8% vs. 49.6% +/- 7.7%, respectively; P = 0.003). After transplantation, patients with a CS > 0 had an EFS inferior to that of patients with a CS of 0 (3-y EFS: 28.9% +/- 6.8% vs. 49.3% +/- 4.9%, respectively [n = 133]; P = 0.009). CONCLUSION: Curie scoring carries prognostic significance in the management of patients with high-risk neuroblastoma. In particular, patients with CSs > 2 after induction have extremely poor outcomes and should be considered for alternative therapeutic strategies.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23440556&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.2967/jnumed.112.112334
dc.subject3-Iodobenzylguanidine
dc.subjectAntibodies
dc.subjectChild
dc.subjectFemale
dc.subjectHumans
dc.subjectInfant
dc.subjectIodine Radioisotopes
dc.subjectMale
dc.subjectNeoplasm Staging
dc.subjectNeuroblastoma
dc.subjectPrognosis
dc.subject*Research Report
dc.subjectStem Cell Transplantation
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectRadiology
dc.titleSemiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
dc.typeJournal Article
dc.source.journaltitleJournal of nuclear medicine : official publication, Society of Nuclear Medicine
dc.source.volume54
dc.source.issue4
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiationoncology_pubs/7
dc.identifier.contextkey5020104
html.description.abstract<p>Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for a cohort of patients with high-risk metastatic disease.</p> <p>METHODS: mIBG scans from 280 patients with mIBG-avid, stage 4 neuroblastoma enrolled on the Children's Oncology Group (COG) protocol A3973 were evaluated at diagnosis (n = 280), after induction chemotherapy (n = 237), and after an autologous stem cell transplantation (n = 178). Individual mIBG scans were evaluated at 10 different anatomic regions, with the scoring of each site (0-3) based on the extent of disease at that anatomic region.</p> <p>RESULTS: There was no correlation between CS at diagnosis and subsequent treatment outcome. Patients with a CS > 2 after induction therapy had a significantly worse event-free survival (EFS) than those with scores 2 identified a cohort of patients at greater risk for an event, independent of other known neuroblastoma factors, including age, MYCN status, ploidy, mitosis-karyorrhexis index, and histologic grade. For MYCN-amplified tumors, the presence (CS > 0) versus absence (CS = 0) of residual mIBG avidity after induction was associated with a significantly worse outcome (3-y EFS: 11.8% +/- 7.8% vs. 49.6% +/- 7.7%, respectively; P = 0.003). After transplantation, patients with a CS > 0 had an EFS inferior to that of patients with a CS of 0 (3-y EFS: 28.9% +/- 6.8% vs. 49.3% +/- 4.9%, respectively [n = 133]; P = 0.009).</p> <p>CONCLUSION: Curie scoring carries prognostic significance in the management of patients with high-risk neuroblastoma. In particular, patients with CSs > 2 after induction have extremely poor outcomes and should be considered for alternative therapeutic strategies.</p>
dc.identifier.submissionpathradiationoncology_pubs/7
dc.contributor.departmentQuality Assurance Review Center
dc.contributor.departmentDepartment of Radiation Oncology
dc.source.pages541-8


This item appears in the following Collection(s)

Show simple item record